Business and Life Sciences executive who provides new market entry and business development services.

Business and Life Sciences executive who is one of the co-founders of Ninja Biotech, LLC with a mission to bring the future to Biotech now. Ninja Biotech was an alliance of companies advancing live cell imaging, bio-imaging probes, data science, and virtual reality applications for the Life Sciences community.

NanoDiagnostics™ (NanoDx™) is a privately held medical device company developing the NanoDx™ System as a point-of-care platform to be used across multiple disease applications. The NanoDx™ System uses a patented nanosensor technology integrated into a disposable cartridge to rapidly detect the presence of biomarkers and infections, such as COVID-19.

Strategic science and business operations services for bioscience and nanotechnology companies. Experienced in working with emerging technologies, technology transfer organizations, and creating commercialization strategies with technology founders.• Chief Technology Officer for EcoPesticides International (New Mexico Angels funded start-up in Santa Fe business incubator), April 2015 – January 2018• DisrupTECH leader (2017) with Feynman Center for Innovation at Los Alamos National Labs.• Approved user for client projects at Center for Integrated Nanotechnologies (CINT) at Sandia National Labs. • Strategic marketing, business and executive team development.• Demonstrated high-level negotiations leading to acquisition.

Recruited to lead development of a noninvasive imaging technology that uses superparamagnetic nanoparticles as the imaging agent with Superconducting Quantum Interference Device (SQUID) sensors for magnetic detection applied to early cancer detection. Responsibilities included leading the science and implementing a broad commercialization strategy providing for a family of product solutions ranging from preclinical research to clinical trials. Primary responsibilities included:• Identifying and managing scientific relationships with key national and regional clinical thought leaders and priority customers.• Author of grant applications as Principal Investigator for NIH RO1, and SBIR Phase I, II, and IIB programs.• Member of senior executive team responsible for obtaining a funding commitment of $2.5M, with upfront payment of $1M to support building two next generation instruments; the second instrument is placed with a collaborating clinical and research team responsible for a state-of-the-art small animal imaging facility at University of Texas MD Anderson Cancer Center.

Founded consulting company to provide market-entry services for a Singapore-based company seeking US customers.

Led business development, marketing, and strategic sales for a nanobiotechnology company developing luciferase activated quantum dot technologies for preclinical in vivo imaging and as an analytical platform for molecular detection.• Established license agreement with Life Technologies (Press Release May 14, 2009).

Led a cross-functional group of 20 people responsible for reagents, assays, applications and new instrument development activities.

Blueshift Biotechnologies, Inc. (founded April 2003, now part of Molecular Devices). Led development of applications and commercialization of a novel laser scanning imaging platform for high throughput multiparametric screening of multiwell plate-based assays for genomics, proteomics, and live cell and small organism imaging applications.Established Cell Biology and Applications Laboratory and managed team to support marketing and sales of the laser scanning platform.

Provided strategic scientific leadership, developed product objectives, managed external collaborations and alliances for laboratory automation, liquid handling solutions, and consumables provider. Helped President execute merger of Labcyte, LLC, with Picoliter, Inc.; an early stage venture funded company with a patented state-of-the-art acoustic technology for liquid handling. Picoliter, Inc. became Labcyte, Inc.

Led implementation of automation, liquid handling tools, HTS equipment and robotics, and new technology platforms for research groups including Antibody Technologies, Assay Development, Molecular Biology, Phage Display, Preclinical Development, and Process Sciences. Led teams integrating reagents, robotics, data capture and data processing to establish robust and efficient systems.• Founded Automation core, established job specification, and hired Automation Specialist responsible for the routine maintenance, troubleshooting, interaction with service engineers, and technology transfer/training on all automation platforms and analysis instruments.• Founded FACS core, established job specification, and hired Specialist for managing the daily operations of two FACSCalibur flow cytometers and a FACS Vantage cell sorter.

Recruited to manage the direction, planning and execution of scientific marketing evaluations to support FDA 510k cleared microvolume fluorimetry assays important for blood banks, AIDS clinics, and oncology applications. Microvolume fluorimetry is based on the analysis of fluorescence in small samples (capillaries, microwells, and chips) and uses a proprietary laser scanning detection system.

Developed strategy, managed scientific staff, and executed research funded by government grants, contracts, and biotechnology-based companies to advance research programs of one of the world's leading independent research and technology development organizations. Established flow cytometry/cell sorting, cell imaging and state-of-the-art bioelectromagnetics research facilities.